Mechanisms of action of mycophenolate mofetil

Lupus

Volumn 14, Issue SUPPL. 1, 2005, Pages

  Allison, A C ^a  

^a SurroMed Inc   (United States)

Author keywords

Antibodies; Arthropathy; Immunosuppressive; Lymphocytes; Monocytes; Nephropathy

Indexed keywords

CALCINEURIN INHIBITOR; CELL ADHESION MOLECULE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; GUANOSINE DERIVATIVE; INOSINATE DEHYDROGENASE INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NUCLEOTIDE; PRODRUG; RITUXIMAB; STEROID; TACROLIMUS; TETRAHYDROBIOPTERIN;

ACUTE GRAFT REJECTION; ALLOGRAFT; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; FIBROGENESIS; GLYCOSYLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MONOCYTE; NEPHROTOXICITY; OSTEOPOROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 16244397067     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120330501400102     Document Type: Article

References (53)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone on the adrenal cortex (17-hydroxy-11-dehydrocorticosterone, compound 8E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949; 24: 181-197.
2. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000; 47: 63-83.
3. Farber S, Toch R, Manning Sears E, Pinkel D. Advances in chemotherapy of cancer in man. In Greenstein HA ed. Advances in cancer research, New York: Academic Press, 1956: 2-73.
4. Friedman RM, Buckler CE, Baron S. The effect of aminomethylpteryl glutamic acid on the development of skin hypersensitivity and antibody formation in guinea pigs. J Exp Med 1961; 114: 173-183.
5. Morabito L, Mortesino MC, Schreibman DM et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires 5′-ectonucleotidase conversion of adenine nucleotides. J Clin Invest 1998; 101: 295-300.
6. Elion GB. The purine path to chemotherapy. Science 1989; 244: 41-47.
7. Murray JE, Merrill JP, Harrison JH et al. Prolonged survival of human kidney hemografts by immunosuppressive drug therapy. N Engl J Med 1963; 268: 1315-1323.
8. Sandborn, WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol 1996; 91: 423-433.
9. Allison, AC. Two lessons from the interface of genetics and medicine. Genetics 2004; 166: 1591-1599.
10. Giblett ER, Anderson JE, Cohen F, Meuwissen HJ. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; II: 1067-1069.
11. Allison AC, Hovi T, Watts RWE, Webster ADB. Immunological observations on patients with the Lesch-Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation. Lancet 1975; II: 1179-1183.
12. Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS-61443. Transplant Proc 1991; 23(Suppl. 2): 10-14.
13. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type 1 and type II IMP dehydrogenases. J Biol Chem 1993; 268: 27286-27292.
14. Allison AC, Eugui EM. Mycophenolate mofetil and its mechansims of action. Immunopharmacology 2000; 47: 85-118.
15. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opinion Pharmacol 2004; 4: 392-397.
16. Nakae S, Saijo S, Horai R, Sudo K, Mon S, Iwakura Y. IL-17 production from activated T-cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003; 100: 5986-5980.
17. Villadsen LS, Schurman J, Blierskens F et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003; 112: 1571-1580.
18. Dillon S, Sprecher C, Hammond A et al. Interleukin 31, a cytokine produced by activated T-cells, induces dermatitis in mice. Nature Immunol 2004; 4: 752-760.
19. Allison, AC. Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. Transpl Proc 2002; 34: 2863-2866.
20. Arbuckle MR, McClain MT, Rubestone MV et al. Development of autoantibodies before the onset of systemic lupus erythematosus. N Eng J Med 2003; 349: 1526-1533.
21. Chan OT, Hannum LG, Haberman AM et al. A novel mouse with B-cells but lacking serum antibody reveals an antibody-independent role for B-cells in murine lupus. J Exp Med 1999; 189: 1639-1648.
22. Looney RJ, Anolik J, Sanz I. B-cells as therapeutic targets for rheumatic diseases. Clin Opin Rheumatol 2004; 16: 180-185.
23. Grailer A, Nichols J, Hullett D, Sollinger HW, Burlingham WJ. Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and FK506. Transplant Proc 1991; 23: 314-315.
24. Theruvath TP, Saidman SL, Mauiyyedi S et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72: 77-83.
25. Daniels MA, Hogquist KA, Jameson SC. Sweet'n'sour: the impact of differential glycosylation on T-cell responses. Nature Immunol 2002; 3: 903-910.
26. Allison AC, Kowalski WJ, Muller CJ et al. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993; 25(Suppl. 2): 67-70.
27. Blaheta RA, Leckel K, Wittig B et al. Mycophenolate mofetil impairs transendothelial migration of allogenic CD4 and CD8 T-cells. Transplant Proc 1999; 31: 1250-1252.
28. Laurent AF, Dumont S, Poindron P, Muller CD. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and some substrates. Exp Hematol 1996; 24: 59-67.
29. Heemann U, Azuma H, Hamar P et al. Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts. Transplant Immunol 1996; 4: 64-67.
30. Utimura R, Fujihara CK, Mattar AL et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003; 63: 209-216.
31. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142.
32. Sugimoto H, Shikata K, Wada J et al. Advanced glycation end products - cytokine nitric oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumor necrosis factor-alpha and inducible nitirc oxide synthase in diabetic rat glomeruli. Diabetologia 1999; 42: 878-886.
33. Senda M, DeLustro B, Eugui E, Natsumeda Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995; 60: 1143-1148.
34. Winlaw DS, Schyvers CG, Smythe GA. Urinary nitrate excretion is a noninvasive indicator of acute cardiac allograft rejection and nitric oxide production in the rat. Transplantation 1994; 58: 1031-1036.
35. Waters RV, Webster D, Allison AC. Mycophenolic acied and some antioxidants induce differentiation of monoytic lineage cells and augment production of the IL-1 receptor antagonist. Ann NY Acad Sci 1993; 696: 185-196.
36. Nadeau KC, Azuma H, Tilney NL. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil. Transplantation 1996; 62: 1363-1366.
37. Zeisberg M, Strutz F, Müller GA. Renal fibrosis: an update. Clin Opin Nephrol Hypertens 2001; 10: 315-320.
38. Eugui EM. Fibrogenesis in chronic allograft rejection: underlying mechanisms and pharmacological control. Traspl Proc 2002; 34: 2867-2871.
39. Dubus I, Vendrely B, Christophe I et al. Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 2002; 62: 857-867.
40. Burke GW, Gancio G, Alejandro R et al. Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK-506 immunosuppression. Transpl Proc 1998; 30: 513-514.
41. Brattström C, Wilczek H, Tyden G et al. Hyperlipidemia in renal transplant patients treated with sirolimus (rapamaycin). Transplantation 1998; 65: 1272-1274.
42. Räisänen-Sokolowski A, Vuoristo P et al. Mycophenolate mofetil (MMF, RS-61443) inhibits proliferation of rat aortic allografts. Transplant Immunol 1995; 3: 343-351.
43. Klupp J, Bamboin C, Hibi K et al. Treatment by mycophenolate mofetil of advanced graft vascular disease in non-human primate recipients of orthotopic aortic allografts. Amer J Transpl. 2003; 3: 1-13.
44. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003; 349: 2379-2380.
45. Zheng L, Nukuna B, Brennan ML et al. Apolipoprotein A-1 is a selective target for myeloperoxidase-catalysed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004; 114: 529-541.
46. Dempster DW. bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989; 4: 137-141.
47. Dissanayake IR, Goodman GR, Bowman AR et al. Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 1998; 65: 275-278.
48. Chang GL, Erdmann GR, Gruber SA et al. Pharmacokinetics of 6-MP, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990; 30: 358-363.
49. Wolberg G. Antipurines and purine metabolism. Handb Exp Pharmacol 1988; 85: 517-530.
50. Dayton JS, Turka LA, Thompson CB, Mitchell BS. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine and mycophenolic acid on T-lymphocyte proliferation and purine metabolism. Molec Pharmacol 1992; 41: 671-676.
51. Hrelia P, Murelli L, Scotti M et al. Organo-specific activation of azathioprine in mice: role of liver metabolism in mutation induction. Carcinogenesis 1988; 9: 1011-1015.
52. Sollinger HW. Mycophenolate in transplantation. Clin Transplant 2004; 18: 485-492.
53. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term remal allograft function deterioration. Transplantation 2003; 75: 1341-1346.